Link to Full Article Melbourne, Australia; 12 January 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic product based on Perrigo’s Testosterone Topical Solution, 30mg/1.5mL. In August 2018, Acrux submitted an Abbreviated New Drug Application (‘ANDA’) to seek approval from […]